CordenPharma Antibiotics Platform

Supply Solutions for Segregated Antibiotics & More

Platform Manager
Dr. Stephen Houldsworth
Director, Global Small Molecules & Antibiotics Platforms, 
CordenPharma International

Stephen.Houldsworth@cordenpharma.com
 
  • Dedicated facilities for segregated antibiotics
  • Multiple manufacturing locations across Europe and USA offering flexibility of supply.
  • Full-service offering and project management from API to final Drug Product, including packaging and labeling in globally approved facilities.
  • Oral & Sterile API & Drug Product solutions.

Platform Description

Through its global manufacturing network, CordenPharma provides Segregated and Non-segregated solutions for antibiotics from development to commercial-scale supply.
Antibiotic APIs are developed and manufactured at CordenPharma Switzerland (CH), CordenPharma Bergamo (IT), CordenPharma Chenôve (FR) and CordenPharma Colorado (USA). Drug product supplies are formulated at CordenPharma Plankstadt (DE) and CordenPharma Caponago (IT).

Beta-Lactam Antibiotics are supplied from CordenPharma Latina (IT) - a dedicated facility adhering to the latest segregation regulations. 

Platform Capabilities

Antibiotics 
  • Non-segregated Antibiotics
    • Development by QbD
    • Oral APIs
    • Oral Drug Products (Tablets & Hard Gel Capsules)
    • Sterile Drug Products (Vials & Pre-filled Syringes)
    • Primary & Secondary Packaging
       
  • Segregated Antibiotics
    • Development by QbD
    • Cephalosporins & Penicillins
      • Sterile APIs
      • Oral Tablets
      • Hard Gel Capsules
      • Sterile Vials
    • Monobactams
    • Primary & Secondary Packaging 

Facilities Included in Platform